Overall, TRIM22 promotes autophagic osteosarcoma cell death and inhibits osteosarcoma progression by promoting NRF2 proteasomal degradation, activating the ROS/AMPK/mTOR/autophagy signaling [38]. Here, NFE2L2 is linked to osteosarcoma.